However, another study evaluating Omalizumab at different doses and frequencies did not demonstrate a significant advantage over the placebo group, and this finding may be less stable and reliable due to the smaller sample size and greater heterogeneity in the second study (20).While there is some controversy regarding the improvement in SCORAD scores, the research indicates that Omalizumab reduces IgE levels in the body (21), improves patients’ quality of life, and may suggest Omalizumab as a treatment option for children with severe atopic dermatitis that is difficult to manage. This evidence concerns the gene IGHE and atopic eczema.